Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.
Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
FDA grants Breakthrough Device Designation to GeneDx genome and exome tests supporting diagnosis of life-threatening genetic disorders. The FDA has granted Breakthrough Device Designation to GeneDx’s ...
Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GeneDx (Nasdaq: WGS), a ...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...
According to Nova One Advisor, the global DNA methylation market size was exhibited at USD 1.75 billion in 2024 and is projected to hit around USD 6.26 billion by 2033, growing at a CAGR of 13.6% ...
As per precedence Research, the global DNA microarray market size is projected to grow approximately USD 6.13 billion by 2034 from valued at USD 2.28 billion in 2023. It is expanding at a CAGR of 9.4% ...
The DNA methylation detection market has grown rapidly in recent years, thanks to advances in technology that allow scientists and healthcare professionals to better understand epigenetic changes. DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback